Castleman's disease is not just a single disease but rather an uncommon, 
heterogeneous group of nonclonal lymphoproliferative disorders, which have a 
broad spectrum of clinical expression. Three histological types have been 
reported, along with several clinical forms according to clinical presentation, 
histological substrate and associated diseases. Interleukin-6, its receptor 
polymorphisms, the human immunodeficiency virus and the human herpes virus 8 are 
involved in the etiopathogenesis of Castleman's disease. The study of this 
disease has shed light on a syndrome whose incidence is unknown. Despite recent 
significant advances in our understanding of this disease and the increasing 
therapeutic experience with rituximab, tocilizumab and siltuximab, there are 
still difficult questions concerning its aetiology, prognosis and optimal 
treatment.